GPOH gGmbH — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

7 Recruiting

1 Completed trials

15 Countries active

31 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 7 Phase II: 1 Phase I (Other): 1

Oversight events:

6 temporary halts across 2 trials

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Nephroblastoma 1

Top IMPs

CYTARABINE, DAUNORUBICIN 2 VINCRISTINE SULFATE 2 CARBOPLATIN 1 CYCLOPHOSPHAMIDE 1 DACTINOMYCIN 1 DOXORUBICIN HYDROCHLORIDE 1 ETOPOSIDE 1 IFOSFAMIDE 1 METHOTREXATE 1 THIOTEPA 1

All trials

9 total

Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending

2024-517133-40-00 Phase III 5 countries
International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting

2024-515245-42-00 Phase I (Other) 4 countries
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc… Recruiting

2022-500676-59-00 Phase II 1 country
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Phase III 6 countries CYTARABINE, DAUNORUBICIN
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Phase III 8 countries
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting

2022-501456-28-00 Phase III 12 countries CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN HYDROCHLORIDE; ETOPOSID…
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica… Recruiting

2022-501454-11-00 Phase III 8 countries
SIOP RANDOMET 2017 Recruiting

2023-508926-91-00 Phase III 10 countries VINCRISTINE SULFATE
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended

2022-501457-37-00 Phase III 7 countries CYTARABINE, DAUNORUBICIN

Showing 1–9 of 9 trials

← All sponsors A–Z